Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 2/20 | 0.52 |
| ▸ | CXCR1 | P25024 | 9/20 | 0.51 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2356688 | 0.94 | SMPD1 (0.52) | SMPD1CXCR1MAPTRAB9ANPC1 | |
| SCHEMBL12243222 | 0.90 | CXCR1 (0.52) | SMPD1CXCR1RARBMAPTGLA | |
| SCHEMBL2363492 | 0.90 | RARB (0.62) | SMPD1CXCR1RARBRAB9ANPC1 | |
| SCHEMBL2351006 | 0.89 | SMPD1 (0.65) | SMPD1CXCR1MAPTRAB9ANPC1 | |
| SCHEMBL6132232 | 0.87 | SMPD1 (0.57) | SMPD1CXCR1MAPTRAB9ANPC1 | |
| SCHEMBL7333704 | 0.87 | SMPD1 (0.63) | SMPD1CXCR1RARBMAPTRAB9A | |
| SCHEMBL6132917 | 0.87 | SMPD1 (0.57) | SMPD1CXCR1MAPTRAB9ANPC1 | |
| SCHEMBL5147869 | 0.87 | SMPD1 (0.63) | SMPD1CXCR1RARBMAPTRAB9A | |
| SCHEMBL12243105 | 0.86 | CXCR1 (0.52) | SMPD1CXCR1RARBRAB9ANPC1 | |
| SCHEMBL2356088 | 0.86 | SMPD1 (0.61) | SMPD1CXCR1RARBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| EP-2350119-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | Merlion Pharmaceuticals Pte Ltd. (SG) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010062264-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | MERLION PHARMACEUTICALS PTE LTD (SG) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | VIP, LTA, CLPTM1 | SMPD1 148/4885CXCR1 301/4885RARB 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.